This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.

Yesterday

There's a lot of hope for ivonescimab, but are investors being a bit too bullish?

Ticker	Sentiment	Impact
SMMT	Neutral	12 %